Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias
Identifieur interne : 002822 ( Main/Corpus ); précédent : 002821; suivant : 002823Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias
Auteurs : C. G. Bachmann ; A. Zapf ; E. Brunner ; C. TrenkwalderSource :
- European Journal of Neurology [ 1351-5101 ] ; 2009-08.
English descriptors
- KwdEn :
Abstract
Background and purpose: Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants. Methods: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication. Results: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m2), 46.4% were normal (BMI > 18.5–25 kg/m2), 33.7% were overweight (BMI > 25–30 kg/m2), 15.7% were obese (BMI > 30 kg/m2). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up. Conclusions: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.
Url:
DOI: 10.1111/j.1468-1331.2009.02617.x
Links to Exploration step
ISTEX:84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title><author><name sortKey="Bachmann, C G" sort="Bachmann, C G" uniqKey="Bachmann C" first="C. G." last="Bachmann">C. G. Bachmann</name><affiliation><mods:affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</mods:affiliation></affiliation><affiliation><mods:affiliation>Paracelsus‐Elena Klinik, Kassel</mods:affiliation></affiliation></author><author><name sortKey="Zapf, A" sort="Zapf, A" uniqKey="Zapf A" first="A." last="Zapf">A. Zapf</name><affiliation><mods:affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brunner, E" sort="Brunner, E" uniqKey="Brunner E" first="E." last="Brunner">E. Brunner</name><affiliation><mods:affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Trenkwalder, C" sort="Trenkwalder, C" uniqKey="Trenkwalder C" first="C." last="Trenkwalder">C. Trenkwalder</name><affiliation><mods:affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</mods:affiliation></affiliation><affiliation><mods:affiliation>Paracelsus‐Elena Klinik, Kassel</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1468-1331.2009.02617.x</idno><idno type="url">https://api.istex.fr/document/84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002822</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title><author><name sortKey="Bachmann, C G" sort="Bachmann, C G" uniqKey="Bachmann C" first="C. G." last="Bachmann">C. G. Bachmann</name><affiliation><mods:affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</mods:affiliation></affiliation><affiliation><mods:affiliation>Paracelsus‐Elena Klinik, Kassel</mods:affiliation></affiliation></author><author><name sortKey="Zapf, A" sort="Zapf, A" uniqKey="Zapf A" first="A." last="Zapf">A. Zapf</name><affiliation><mods:affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brunner, E" sort="Brunner, E" uniqKey="Brunner E" first="E." last="Brunner">E. Brunner</name><affiliation><mods:affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Trenkwalder, C" sort="Trenkwalder, C" uniqKey="Trenkwalder C" first="C." last="Trenkwalder">C. Trenkwalder</name><affiliation><mods:affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</mods:affiliation></affiliation><affiliation><mods:affiliation>Paracelsus‐Elena Klinik, Kassel</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-08">2009-08</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="895">895</biblScope><biblScope unit="page" to="901">901</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444</idno><idno type="DOI">10.1111/j.1468-1331.2009.02617.x</idno><idno type="ArticleID">ENE2617</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>body weight</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and purpose: Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants. Methods: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication. Results: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m2), 46.4% were normal (BMI > 18.5–25 kg/m2), 33.7% were overweight (BMI > 25–30 kg/m2), 15.7% were obese (BMI > 30 kg/m2). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up. Conclusions: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>C. G. Bachmann</name><affiliations><json:string>Department of Clinical Neurophysiology, Georg August University, Göttingen</json:string><json:string>Paracelsus‐Elena Klinik, Kassel</json:string></affiliations></json:item><json:item><name>A. Zapf</name><affiliations><json:string>Department of Medical Statistics, Georg August University, Göttingen, Germany</json:string></affiliations></json:item><json:item><name>E. Brunner</name><affiliations><json:string>Department of Medical Statistics, Georg August University, Göttingen, Germany</json:string></affiliations></json:item><json:item><name>C. Trenkwalder</name><affiliations><json:string>Department of Clinical Neurophysiology, Georg August University, Göttingen</json:string><json:string>Paracelsus‐Elena Klinik, Kassel</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>body weight</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson’s disease</value></json:item></subject><articleId><json:string>ENE2617</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background and purpose: Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants. Methods: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication. Results: Analysis showed that 4.2% of PD patients were underweight (BMI > 18.5 kg/m2), 46.4% were normal (BMI > 18.5–25 kg/m2), 33.7% were overweight (BMI > 25–30 kg/m2), 15.7% were obese (BMI > 30 kg/m2). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up. Conclusions: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.</abstract><qualityIndicators><score>6.271</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1427</abstractCharCount><pdfWordCount>3847</pdfWordCount><pdfCharCount>23666</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>202</abstractWordCount></qualityIndicators><title>Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title><genre><json:string>article</json:string></genre><host><volume>16</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>7</total><last>901</last><first>895</first></pages><issn><json:string>1351-5101</json:string></issn><issue>8</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1111/j.1468-1331.2009.02617.x</json:string></doi><id>84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title><author><persName><forename type="first">C. G.</forename><surname>Bachmann</surname></persName><affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</affiliation><affiliation>Paracelsus‐Elena Klinik, Kassel</affiliation></author><author><persName><forename type="first">A.</forename><surname>Zapf</surname></persName><affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</affiliation></author><author><persName><forename type="first">E.</forename><surname>Brunner</surname></persName><affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</affiliation></author><author><persName><forename type="first">C.</forename><surname>Trenkwalder</surname></persName><affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</affiliation><affiliation>Paracelsus‐Elena Klinik, Kassel</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-08"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="895">895</biblScope><biblScope unit="page" to="901">901</biblScope></imprint></monogr><idno type="istex">84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444</idno><idno type="DOI">10.1111/j.1468-1331.2009.02617.x</idno><idno type="ArticleID">ENE2617</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background and purpose: Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants. Methods: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication. Results: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m2), 46.4% were normal (BMI > 18.5–25 kg/m2), 33.7% were overweight (BMI > 25–30 kg/m2), 15.7% were obese (BMI > 30 kg/m2). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up. Conclusions: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>body weight</term></item><item><term>levodopa</term></item><item><term>Parkinson’s disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="08008"><doi origin="wiley">10.1111/ene.2009.16.issue-8</doi><numberingGroup><numbering type="journalVolume" number="16">16</numbering><numbering type="journalIssue" number="8">8</numbering></numberingGroup><coverDate startDate="2009-08">August 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="4" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2009.02617.x</doi><idGroup><id type="unit" value="ENE2617"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><copyright>© 2009 The Author(s). Journal compilation © 2009 EFNS</copyright><eventGroup><event type="firstOnline" date="2009-04-03"></event><event type="publishedOnlineFinalForm" date="2009-07-15"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="895">895</numbering><numbering type="pageLast" number="901">901</numbering></numberingGroup><correspondenceTo>Cornelius G. Bachmann, MD, Department of Clinical Neurophysiology, Georg August University, Robert Koch Strasse 40, D‐37075 Göttingen, Germany (tel.: +49‐551‐39‐6650; fax: +49‐551‐39‐12651; e‐mail: <email>cbachma@gwdg.de</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE2617.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 24 November 2008 Accepted 18 February 2009</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count></countGroup><titleGroup><title type="main">Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title><title type="shortAuthors">C. G. Bachmann <i>et al.</i></title><title type="short">Dopaminergic treatment is associated with decreased body weight in advanced PD</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1 #a2"><personName><givenNames>C. G.</givenNames><familyName>Bachmann</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a3"><personName><givenNames>A.</givenNames><familyName>Zapf</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>E.</givenNames><familyName>Brunner</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1 #a2"><personName><givenNames>C.</givenNames><familyName>Trenkwalder</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>Paracelsus‐Elena Klinik, Kassel</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="DE"><unparsedAffiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">body weight</keyword><keyword xml:id="k2">levodopa</keyword><keyword xml:id="k3">Parkinson’s disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Background and purpose: </b> Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants.</p><p><b>Methods: </b> Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication.</p><p><b>Results: </b> Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m<sup>2</sup>), 46.4% were normal (BMI > 18.5–25 kg/m<sup>2</sup>), 33.7% were overweight (BMI > 25–30 kg/m<sup>2</sup>), 15.7% were obese (BMI > 30 kg/m<sup>2</sup>). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up.</p><p><b>Conclusions: </b> In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title></titleInfo><titleInfo type="abbreviated"><title>Dopaminergic treatment is associated with decreased body weight in advanced PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias</title></titleInfo><name type="personal"><namePart type="given">C. G.</namePart><namePart type="family">Bachmann</namePart><affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</affiliation><affiliation>Paracelsus‐Elena Klinik, Kassel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Zapf</namePart><affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Brunner</namePart><affiliation>Department of Medical Statistics, Georg August University, Göttingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Trenkwalder</namePart><affiliation>Department of Clinical Neurophysiology, Georg August University, Göttingen</affiliation><affiliation>Paracelsus‐Elena Klinik, Kassel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2009-08</dateIssued><edition>Received 24 November 2008 Accepted 18 February 2009</edition><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent></physicalDescription><abstract lang="en">Background and purpose: Several studies suggested that patients with advanced Parkinson’s disease (PD) showed a too low body weight when compared with age‐matched, healthy subjects. We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative determinants. Methods: Charts of 166 PD patients with fluctuations and dyskinesias, admitted within 6 months to a German movement disorders clinic, were investigated for body mass index (BMI), age at onset, disease duration, Unified Parkinson’s Disease Rating Scale motor score, eating coordination and medication. Results: Analysis showed that 4.2% of PD patients were underweight (BMI < 18.5 kg/m2), 46.4% were normal (BMI > 18.5–25 kg/m2), 33.7% were overweight (BMI > 25–30 kg/m2), 15.7% were obese (BMI > 30 kg/m2). Daily levodopa dosage per kg and total dopaminergic dosage per kg body weight were negatively correlated with BMI. Overall, patients’ BMI had not significantly changed within 2 years of follow‐up. Conclusions: In sum, advanced PD patients showed a reduced BMI when compared with a control population obtained from an age‐matched group taken from a survey of the German Federal Office for Statistics. Our findings indicate that patients with a lower BMI received a higher cumulative levodopa dosage and that levodopa may be responsible for weight loss in PD.</abstract><subject lang="en"><genre>Keywords</genre><topic>body weight</topic><topic>levodopa</topic><topic>Parkinson’s disease</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>895</start><end>901</end><total>7</total></extent></part></relatedItem><identifier type="istex">84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444</identifier><identifier type="DOI">10.1111/j.1468-1331.2009.02617.x</identifier><identifier type="ArticleID">ENE2617</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2009 The Author(s). Journal compilation © 2009 EFNS</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:84D1AA97CFA07FF67CD099BD0CC6D7A5B5449444
|texte= Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias
}}
| This area was generated with Dilib version V0.6.23. |  |